JP2023542608A5 - - Google Patents
Info
- Publication number
- JP2023542608A5 JP2023542608A5 JP2023507542A JP2023507542A JP2023542608A5 JP 2023542608 A5 JP2023542608 A5 JP 2023542608A5 JP 2023507542 A JP2023507542 A JP 2023507542A JP 2023507542 A JP2023507542 A JP 2023507542A JP 2023542608 A5 JP2023542608 A5 JP 2023542608A5
- Authority
- JP
- Japan
- Prior art keywords
- prostate cancer
- subject
- antagonist
- composition according
- glucocorticoid receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061013P | 2020-08-04 | 2020-08-04 | |
| US63/061,013 | 2020-08-04 | ||
| US202163226102P | 2021-07-27 | 2021-07-27 | |
| US63/226,102 | 2021-07-27 | ||
| PCT/US2021/044255 WO2022031642A2 (en) | 2020-08-04 | 2021-08-03 | Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542608A JP2023542608A (ja) | 2023-10-11 |
| JP2023542608A5 true JP2023542608A5 (enExample) | 2024-07-30 |
Family
ID=80118471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507542A Pending JP2023542608A (ja) | 2020-08-04 | 2021-08-03 | グルココルチコイド受容体（ｇｒ）アンタゴニストおよびアンドロゲン受容体（ａｒ）分解誘導剤の組み合わせの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230302014A1 (enExample) |
| EP (1) | EP4192460A4 (enExample) |
| JP (1) | JP2023542608A (enExample) |
| CN (1) | CN116322694A (enExample) |
| WO (1) | WO2022031642A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| KR20230017829A (ko) | 2020-05-27 | 2023-02-06 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c8과 cyp3a4의 이중 기질인 파클리탁셀의 병용 투여 |
| WO2024006527A1 (en) * | 2022-07-01 | 2024-01-04 | Arvinas Operations, Inc. | Breast cancer treatment method |
| US20240091218A1 (en) * | 2022-09-02 | 2024-03-21 | Corcept Therapeutics Incorporated | Methods of treating prostate cancer using exicorilant and enzalutamide |
| US12433882B2 (en) | 2022-10-28 | 2025-10-07 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| WO2024220926A1 (en) * | 2023-04-21 | 2024-10-24 | Arvinas Operations, Inc. | Use of an androgen receptor degrader protac for the treatment of prostate cancer |
| WO2024233696A1 (en) * | 2023-05-09 | 2024-11-14 | Arvinas Operations, Inc. | Bavdegalutamide for treating prostate cancer without ar l702h mutation |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017112902A1 (en) * | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| LT3660004T (lt) * | 2016-10-11 | 2023-06-12 | Arvinas Operations, Inc. | Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai |
| CA3100513A1 (en) * | 2018-05-16 | 2019-11-21 | Gtx, Inc. | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
-
2021
- 2021-08-03 JP JP2023507542A patent/JP2023542608A/ja active Pending
- 2021-08-03 US US18/007,369 patent/US20230302014A1/en active Pending
- 2021-08-03 EP EP21852221.7A patent/EP4192460A4/en not_active Withdrawn
- 2021-08-03 CN CN202180068343.XA patent/CN116322694A/zh active Pending
- 2021-08-03 WO PCT/US2021/044255 patent/WO2022031642A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lacal et al. | Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors | |
| JP2023098947A5 (enExample) | ||
| EP2783686B1 (en) | Combination of a rapamycin derivative and letrozole for treating breast cancer | |
| JP2020516646A5 (enExample) | ||
| JP7141408B2 (ja) | 前立腺癌の併用療法 | |
| JP2019510832A5 (enExample) | ||
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| JP2018513123A5 (enExample) | ||
| JP2022500479A5 (enExample) | ||
| JP2019526632A5 (enExample) | ||
| JP2022501383A5 (enExample) | ||
| EP4218820A2 (en) | Combination therapies for the treatment of breast cancer | |
| WO2020051294A1 (en) | The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer | |
| Shagisultanova et al. | Safety and efficacy of tucatinib, letrozole, and palbociclib in patients with previously treated HR+/HER2+ breast cancer | |
| JP2023175825A (ja) | 肝細胞癌の治療のための併用療法 | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| JP2022058873A5 (enExample) | ||
| JP2024529430A5 (enExample) | ||
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| TW202227068A (zh) | 組合藥物療法 | |
| CN110464845A (zh) | 一种用于乳腺癌免疫治疗的联合用药物组合及其应用 | |
| JP2023514056A5 (enExample) | ||
| JP2025038130A (ja) | エストロゲン受容体アルファ阻害剤の経口剤形を用いて癌を治療する方法 | |
| WO2020239051A1 (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 |